×
0 0 0 0 0 0 0 0
Stockreport

Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes

LEXICON PHARMACEUTICALS (LXRX)  More Company Research Source: GlobeNewswire
Last lexicon pharmaceuticals earnings: 11/8 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: lexpharma.com/investors
PDF THE WOODLANDS, Texas, March 29, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) filed by Lexicon’s collaborator, Sanofi, for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for use in combination with insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus. “By accepting the MAA filing, the EMA acknowledges the need for a new treatment option for people suffering from type 1 diabetes to address the debilitating effects of this disease,” said Pablo Lapuerta, M.D., executive vice president and chief medical officer. “We and our collaborator, Sanofi, plan to work closely with the EMA and Committee for Medicinal Products for Human Use (CHMP) toward the goal of bringing sotagliflozin to people living with type 1 diabetes in Europe as quickly as possible.” “Type 1 diabetes is an escalating epidemic tha [Read more]

IMPACT SNAPSHOT EVENT TIME: LXRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS